Britain’s National Health Service announced on Friday that it would limit the use of puberty-suppressing drugs to children enrolled in clinical trials. The change comes as the agency’s pediatric gender services have struggled to keep up with soaring demand.

Rating: Transneutral, New York Times, June 9, 2023 (PDF archive)